Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, Jun ^a   Chen, Lei ^a   Zhang, Xiaofeng ^a   Zhang, Yu ^a   Liu, Huiying ^a   Sun, Bin ^a   Zhao, Linlin ^a   Ge, Naijian ^a   Qian, Haihua ^a   Yang, Yefa ^a   Wu, Mengchao ^a   Yin, Zhengfeng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; CARBAMOYL PHOSPHATE SYNTHASE; CARBAMOYL PHOSPHATE SYNTHASE 1 ANTIBODY; CYTOKERATIN; MONOCLONAL ANTIBODY; PANCYTOKERATIN; PANCYTOKERATIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; KERATIN;

ADULT; ARTICLE; BLOOD SAMPLING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANIMALS; ANTIBODIES; ASIALOGLYCOPROTEIN RECEPTOR; CARBAMOYL-PHOSPHATE SYNTHASE (AMMONIA); CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; HUMANS; KERATINS; LIVER NEOPLASMS; MICE, INBRED BALB C; NEOPLASTIC CELLS, CIRCULATING;

EID: 84899716878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096185     Document Type: Article

References (40)

1. Alix-Panabières C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59: 110-118.
2. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
3. Kang Y, Pantel K (2013) Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23: 573-581.
4. Gorges TM, Pantel K (2013) Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother 62: 931-939.
5. Lianidou ES, Markou A, Strati A (2012) Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer Metastasis Rev 31: 663-671.
6. Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, et al. (2011) Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res 17: 337-345.
7. Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW, et al. (2010) Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol 10: 35.
8. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW (2010) All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 21: 1851-1857.
9. Deng G, Herrler M, Burgess D, Manna E, Krag D, et al. (2008) Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 10: R69.
10. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, et al. (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 106: 3970-3975.
11. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, et al. (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 130: 1590-1597.
12. Gazzaniga P, Gianni W, Raimondi C, Gradilone A, Lo Russo G, et al. (2013) Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumour Biol 34: 2507-2509.
13. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13: 920-928. (Pubitemid 46340368)
14. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV (1999) Expression of EpCAM in normal, regenerating, metaplastic and neoplastic liver. J Pathol 188: 201-206.
15. Proca DM, Niemann TH, Porcell AI, DeYoung BR (2000) MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report findings and review of other utilized markers. Appl Immunohistochem Mol Morphol 8: 120-125. (Pubitemid 30609972)
16. Porcell AI, De Young BR, Proca DM, FrankelWL (2000) Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 13: 773-778. (Pubitemid 30470167)
17. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, et al. (2004) Frequent EpCAM protein expression in human carcinomas. Hum Pathol 35: 122-128. (Pubitemid 38133932)
18. Zhang Y, Li J, Cao L, Xu W, Yin Z (2012) Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 39: 449-460.
19. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, et al. (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133: 2165-5171.
20. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, et al. (2013) Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57: 1458-1468.
21. Xu W, Cao L, Chen L, Li J, Zhang XF, et al. (2011) Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 17: 3783-3793.
22. Stockert RJ, Morell AG (1983) Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. Hepatology 3: 750-757. (Pubitemid 13007704)
23. Ashwell G, Morell AG (1974) The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 41: 99-128.
24. Butler SL, Dong H, Cardona D, Jia M, Zheng R, et al. (2008) The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 88: 78-88.
25. Almeida AP, Beaven MA (1980) Gel formation with leucocytes and heparin. Life Sci 26: 549-555. (Pubitemid 10064304)
26. Dirlam-Schatz KA, Attie AD (1998) Calcium induces a conformational change in the ligand binding domain of the low density lipoprotein receptor. J Lipid Res 39: 402-411. (Pubitemid 28100677)
27. Wragg S, Drickamer K (1999) Identification of amino acid residues that determine pH dependence of ligand binding to the asialoglycoprotein receptor during endocytosis. J Biol Chem 274: 35400-35406. (Pubitemid 129512830)
28. Zijderhand-Bleekemolen JE, Schwartz AL, Slot JW, Strous GJ, Geuze HJ (1987) Ligand- and weak base-induced redistribution of asialoglycoprotein receptors in hepatoma cells. J Cell Biol 104: 1647-1654. (Pubitemid 17104534)
29. Liu H, Dong H, Robertson K, Liu C (2011) DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol 178: 652-661.
30. Timek DT, Shi J, Liu H, Lin F (2012) Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 138: 203-210.
31. Siddiqui MT, Saboorian MH, Gokaslan ST, Ashfaq R (2002) Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples. Cancer 96: 49-52. (Pubitemid 34194320)
32. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, et al. (2008) Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10: R80.
33. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, et al. (2011) Detection of circulating tumour cells with a hybrid (epithelial/ mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105: 1338-1341.
34. Nel I, Baba HA, Ertle J, Weber F, Sitek B, et al. (2013) Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 6: 420-428.
35. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
36. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, et al. (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361.
37. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, et al. (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339: 580-584.
38. Radisky DC, LaBarge MA (2008) Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2: 511-512. (Pubitemid 351729219)
39. Attard G, de Bono JS (2011) Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 21: 50-58.
40. Wicha MS, Hayes DF (2011) Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 29: 1508-1511.